Company Overview and News

5
PTGX / Protagonist Therapeutics, Inc. S-8

2018-05-30 sec.gov
As filed with the Securities and Exchange Commission on May 30, 2018. Registration No. 333-
PTGX

2
PTGX / Protagonist Therapeutics, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G (Passive Investment)

2018-05-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (R
PTGX

3
PTGX / Protagonist Therapeutics, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G (Passive Investment)

2018-05-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (R
PTGX

2
On World IBD Day Biotech Companies Continue to Develop IBD Treatments

2018-05-18 biospace
Severe diarrhea. Bloody stool. Abdominal pain. Fatigue. Reduced appetite. Weight loss. These are the general symptoms of chronic inflammatory diseases of the digestive tract grouped under the term inflammatory bowel disease.
PTGX

2
PTGX / Protagonist Therapeutics, Inc. DEFA14A

2018-05-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PTGX

16
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down

2018-05-10 zacks
Puma Biotechnology, Inc. (PBYI - Free Report) reported a loss of 65 cents for the first-quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 75 cents and the year-ago loss of $1.97.
LGNZZ LGND LGNYZ PBYI LGNXZ PTGX LGNDZ

6
PTGX / Protagonist Therapeutics, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov
ptgx_Current_Folio_10Q Table of Contents
PTGX

82
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View

2018-05-09 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported a loss of 18 cents per share in first-quarter 2018, in line with the Zacks Consensus Estimate. The company had reported a loss of 21 cents in the year-ago quarter.
LGNDZ INFI ODP GM.WS.A GM.WS.B LGNZZ LGND GM.WS.C LGNYZ LGNXZ PTGX GM GM.WSB

7
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1

2018-05-09 zacks
Epizyme, Inc. (EPZM - Free Report) incurred a loss of 49 cents per share in the first quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 54 cents as well as the year-ago loss of 56 cents.
EPZM LGNDZ GM.WS.A LGNZZ GM.WS.B LGND LGNYZ GM.WS.C LGNXZ PTGX GM GM.WSB

29
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1

2018-05-09 zacks
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) reported a loss of $1.33 per share for the first quarter of 2018, which was wider than the Zacks Consensus Estimate of a loss of $1.28. The company had reported a loss of $2.20 in the year-ago quarter.
MACK LGNZZ LGND LGNYZ LGNXZ MYGN PTGX LGNDZ

12
Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates

2018-05-09 zacks
Jazz Pharmaceuticals plc (JAZZ - Free Report) reported adjusted earnings of $2.98 per share for first-quarter 2018, which beat the Zacks Consensus Estimate of $2.76. Earnings rose 29% from the year-ago figure.
JAZZ LGNZZ LGND LGNYZ LGNXZ MYGN PTGX LGNDZ ONCE

39
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected

2018-05-09 zacks
Arena Pharmaceuticals, Inc. (ARNA - Free Report) reported a loss of 78 cents per share for the first quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 70 cents. The year-ago loss was 90 cents per share.
ARNA EXEL LGNZZ LGND LGNYZ LGNXZ MYGN PTGX LGNDZ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 74366E102